Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04596722 · ClinicalTrials.gov registry record · NA
Oral Pomegranate Extract on the Microbiome and Skin Biophysical Properties
A NA study, sponsored by Integrative Skin Science and Research.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT04596722 is a NA study that has completed, run by Integrative Skin Science and Research. The registered enrollment target is 18 participants.
The verdict
NCT04596722, a NA study, has completed, sponsored by Integrative Skin Science and Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
Pomegranate extract (Pomella) is well known for its antioxidant properties due to its phenolic compounds. It has also been shown to increase the amount of short chain fatty acid producing Lactobacillus and Bifidobacteria genera. Short chain fatty acids are thought to have an anti-inflammatory effect on the sebaceous glands. Previous studies have concluded that pomegranate extract may act as a prebiotic in the body and subsequently increasing the gastrointestinal microbial diversity and by producing short chain fatty acids that may have systemic beneficial effects especially on the skin. Therefore, the aim of this study is to assess how Pomella alters the gut microbiome and the blood level of short chain fatty acids in healthy subjects.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Pomella
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2021-03-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04596722
The ClinicalTrials.gov registry entry for NCT04596722 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integrative Skin Science and Research, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04596722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04596722 about?
NCT04596722 is a clinical study titled "Oral Pomegranate Extract on the Microbiome and Skin Biophysical Properties". Pomegranate extract (Pomella) is well known for its antioxidant properties due to its phenolic compounds. It has also been shown to increase the amount of short chain fatty acid producing Lactobacillus and Bifidobacteria genera. Short chain fatty acids are thought to have an anti-inflammatory effect...
What is the current status of trial NCT04596722?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2020-11-09. Estimated completion is 2021-03-24.
What interventions are being tested in trial NCT04596722?
The interventions under investigation include: Placebo (OTHER), Pomella (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04596722?
This trial is sponsored by Integrative Skin Science and Research, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.